studies on retatrutide Eli Lilly's Phase 3 clinical investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Retatrutide: What It Is &

This is less commonly observed with Tirzepatide, which lacks glucagon activity

As lawsuits mount nationwide, West Virginians find themselves at the heart of this issue, given the states significant reliance on such medications

User Login Lost Password

With integrative care at TrMD, well look at the full picture of your health, optimize nutrition and lifestyle, use targeted interventions, and monitor to avoid unwanted side effects

In clinical studies , people lost approximately 2% of their baseline body weight by the end of the first month

Currently, three of the incretin-based products are FDA approved for weight loss Wegovy (semaglutide), Saxenda (liraglutide), and Zepbound (tirzepatide)